Scholar Rock Holding Azioni (NASDAQ: SRRK)

Ultime notizie per Scholar Rock Holding (NASDAQ:SRRK) Azioni

Scholar Rock Holding

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding Corp

<p>This Comparable RevPAR reflects an approximate decrease of&nbsp;1.6%&nbsp;compared to the&nbsp;third quarter&nbsp;of 2023.&nbsp;</p>
<p>Additionally, for the month of&nbsp;July 2024, Comparable RevPAR increased approximately&nbsp;0.3%&nbsp;versus&nbsp;July 2023. For the month of&nbsp;August 2024, Comparable RevPAR decreased approximately&nbsp;2.1%&nbsp;versus&nbsp;August 2023. For the month of&nbsp;September 2024, Comparable RevPAR decreased approximately&nbsp;3.0%&nbsp;versus&nbsp;September 2023. &nbsp;</p>
<p>Further, as previously announced, the Company commenced the offering of its Non-Traded Preferred Equity during the&nbsp;third quarter&nbsp;of 2022.&nbsp;</p>


News

Ashford Hospitality Trust Expects To Report Occupancy Of Approximately 71% For Q3 With Average Daily Rate Of $187 Resulting In RevPAR Of Approximately $132

<p>Wells Fargo  analyst Sam Reid   maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Overweight and raises the price target from $90 to $92.</p>


Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Masco, Raises Price Target to $92

WIIM

PENN

PENN Entertainment shares are trading higher after the company reportedly guided Q3 retail operations adjusted EBITDAR of $465M-$475M.

<p>Wells Fargo  analyst Joe O'Dea   maintains Trane Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) with a Underweight and raises the price target from $320 to $360.</p>


Wells Fargo Maintains Underweight on Trane Technologies, Raises Price Target to $360

<p>Wells Fargo  analyst Joseph O'Dea   maintains Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) with a Equal-Weight and lowers the price target from $110 to $104.</p>


Wells Fargo Maintains Equal-Weight on Stanley Black & Decker, Lowers Price Target to $104

<p>Researchers from Emory University, the University of Wisconsin-Madison and UC-Berkeley have identified a significant opportunity for <a href="https://www.benzinga.com/topic/psilocybin-assisted-therapy">psilocybin-assisted therapy</a> in the U.S. mental healthcare landscape. As U.S. News <a href="https://www.usnews.com/news/health-news/articles/2024-09-13/over-5-million-americans-could-benefit-if-psilocybin-approved-for-depression-study">reported</a>, if approved by the <a href="https://www.benzinga.com/topic/food-and-drug-administration">FDA</a>, psilocybin could be used to treat depression, with an estimated<strong> 5.1 to 5.6 million</strong> Americans potentially benefiting from the therapy.</p>
<p>Examining a group of patients undergoing treatment for depression, researchers determined that psilocybin could be a game-changing solution, particularly for individuals suffering from major depressive disorder (MDD) or treatment-resistant depression (TRD). These conditions, which affect millions across the country, are typically unresponsive to standard treatments, underscoring the urgent need for new solutions.</p>
<h3 class="wp-block-heading"><strong>A Breakthrough Approach To Treating Depression</strong></h3>
<p>The study, <a href="https://pp.genomicpress.com/wp-content/uploads/2024/09/PP0025-Rab-2024.pdf">published</a> in Psychedelics<em> </em>by Genomic Press, explored the FDA's consideration of psilocybin from <a href="https://www.benzinga.com/markets/cannabis/22/11/29549541/the-strongest-magic-mushroom-species">Psilocybe cubensis</a> mushrooms as a <a href="https://www.benzinga.com/general/biotech/24/03/37665900/fda-grants-cybin-breakthrough-therapy-status-for-major-depression-psilocybin-therapy-company-anno">breakthrough therapy,</a> which is a designation that allows drugs with the potential to address life-threatening conditions like severe depression, to be fast-tracked through the approval process. If green-lighted, psilocybin would likely be reserved for individuals with the most severe forms of depression or those who have not responded to traditional treatments.</p>
<p>The study found that some 1.7 million Americans with TRD could immediately benefit from psilocybin-assisted therapy. When including those with MDD, the number of potential beneficiaries rises to 5.6 million. <strong>Dr. Syed Fayzan Rab</strong>, an MD candidate at Emory University and the study's lead author, highlighted the importance of recognizing the scope of this opportunity. "This underscores the importance of understanding the practical realities of rolling out this novel treatment on a large scale."</p>
<h3 class="wp-block-heading"><strong>A Market Ready To Take Off</strong></h3>
<p>Implications of this study go beyond healthcare. The psilocybin-assisted therapy market holds immense economic potential. A 2023 <a href="https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1293243/full">report</a> estimated that a single psilocybin-assisted therapy session could cost around $1,500 per patient. Considering the millions of individuals who may be eligible for treatment, this could translate into billions of dollars in revenue once psilocybin gains FDA approval.</p>
<p>Several companies are already preparing to capitalize on this potential market. <strong>Compass Pathways</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>), <strong>Atai Life Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) and <strong>Mindset Pharma</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MSSTF#OTC">MSSTF</a>) are among the pharmaceutical firms actively developing psilocybin-based treatments. </p>
<h3 class="wp-block-heading"><strong>Beyond Depression: Psilocybin's Expanding Horizon</strong></h3>
<p>While psilocybin's most immediate application lies in depression treatment, its therapeutic potential extends further. Ongoing studies are investigating psilocybin's efficacy in treating chronic pain and <a href="https://www.benzinga.com/topic/ptsd">post-traumatic stress disorder</a>. These developments signal that psilocybin could revolutionize not just mental healthcare but also the treatment of other chronic conditions.</p>
<p>However, psilocybin remains classified as a <a href="https://www.benzinga.com/topic/controlled-substances-act">Schedule I</a> drug at the federal level, meaning it is considered to have no accepted medical use and a high potential for abuse. This classification, shared with substances like marijuana, heroin and <a href="https://www.benzinga.com/topic/lsd">LSD</a>, complicates the path toward legalizing its medical use. </p>
<p>Despite these federal restrictions, several U.S. states and local jurisdictions have <a href="https://www.benzinga.com/topic/psychedelics-decriminalization">decriminalized psilocybin</a> in recent years, signaling a growing push for policy reform at higher levels. </p>
<p>"It's our hope that these findings spur productive discussions and proactive preparations to optimize the benefit to patients while minimizing unintended consequences," said <strong>Dr. Charles Raison</strong>, a professor of psychiatry at the University of Wisconsin and co-author of the study.  </p>
<p><em>Cover image made with A</em>I</p>


Cannabis

Psychedelics

Regulations

Health Care

ATAI

CMPS

MSSTF

Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes

<p>Wells Fargo  analyst Joseph O'Dea   maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Overweight and raises the price target from $293 to $305.</p>


Wells Fargo Maintains Overweight on Rockwell Automation, Raises Price Target to $305

Guidance

Penn Entertainment Expects Q3 Retail Operations Adj EBITDAR In Range $465M-$475M

<ul>
<li><i>Companies jointly propose electric transmission projects to serve region's growing power demand through&nbsp;PJM's competitive planning process</i></li>
<li><i>Collaboration leverages expertise of industry leaders to propose comprehensive, cost-effective solutions that promote regional grid reliability</i></li>
</ul>
<p>RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Dominion Energy Virginia, American Electric Power and FirstEnergy Corp. have entered into an innovative joint planning agreement to propose several new regional electric transmission projects across multiple states within the PJM footprint.&nbsp;</p>
<p>The innovative collaboration comes at a time when efficient and cost-effective regional transmission development is essential and encouraged by the Federal Energy Regulatory Commission (FERC), the independent federal agency that regulates the interstate transmission of electricity.</p>
<p>Power demand in the PJM region is growing at an unprecedented pace due to rapid expansion of energy-intensive industries such as data centers, the electrification of transportation and heating, and increased manufacturing onshoring. At the same time, the region's power generation mix is changing as legacy generation is retired and more renewables are added to the grid.</p>


Dominion Energy, American Electric Power, FirstEnergy Reach Joint Planning Agreement To Propose Regional Transmission Projects Across PJM Footprint To Propose Comprehensive, Cost-Effective Solutions That Promote Regional Grid Reliability

ELAN

Elanco shares are trading higher after the company received FDA approval for Credelio Quattro broad-spectrum canine oral parasiticide in a monthly dose.

<div>
<div><strong>Nutanix</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntnx#NASDAQ">NTNX</a>) shares have returned 26.2% year to date, outperforming the broader Zacks Computer and Technology sector&#39;s appreciation of 23.4%.</div>
<div>NTNX shares have also outperformed the Zacks Computer &ndash; IT Services industry and its peers like <strong>Unisys</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uis#NYSE">UIS</a>), <strong>Evolv Technologies</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlv#NASDAQ">EVLV</a>) and <strong>Cerence</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crnc#NASDAQ">CRNC</a>).</div>
<div>Over the same time frame, Unisys has appreciated 0.2%, while Evolv Technologies and Cerence have declined 19.7% and 86.3%, respectively. The industry has appreciated 9.2% YTD.</div>
<div>NTNX&#39;s outperformance can be attributed to the steady adoption of hybrid cloud solutions, an increase in renewal and subscription business, and an expanding clientele.&nbsp;</div>
<div class="chart_embed">
<h2>Nutanix Price and Consensus</h2>
<p><img alt="Nutanix Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/a2/1728310394.png" style="height:265px; width:581px" title="" /></p>
<p>Nutanix price-consensus-chart | Nutanix Quote</p>
</div>
<h2>Does Strong Clientele Justify NTNX&#39;s Premium Valuation?</h2>
<div>In fiscal 2024, approximately 76% of NTNX&#39;s end customers who have been its clients for 18 months or longer made a repeat purchase, reflecting a loyal customer base. Nutanix&#39;s total revenues for fiscal 2024 were $2.14 billion, of which 93.8% was from subscriptions.</div>
<div>NTNX stacks are usable with a vast library of operating systems like Microsoft and SAP, and existing customers have benefited from the hyper-converged infrastructure market.</div>
<div>However, NTNX shares are overvalued, as suggested by a Value Score of F.</div>
<div>In terms of the forward 12-month Price/Earnings ratio, NTNX is trading at 178.5X, higher than the Zacks Computer &amp; Technology sector&#39;s 26.83X.</div>
<div>So, the question for investors is - does an expanding clientele make Nutanix shares attractive despite a stretched valuation? Let&#39;s analyze.</div>
<h2>NTNX&#39;s Cloud Innovation Aids Prospects</h2>
<div>Nutanix is focusing on new releases and enhancements to the Nutanix Cloud Platform to aid long-term opportunities and to become a leader in modern application and data management platforms.</div>
<div>NTNX expanded its 14-year partnership with Dell Technologies to announce innovations like Dell XC Plus and Dell PowerFlex.</div>
<div>Nutanix Cloud Platform enables businesses to modernize IP footprints, integrate hybrid cloud models, and accelerate migration of workload to the public cloud to enhance cost-effectiveness and efficiency.</div>
<div>NTNX recently launched GPT-in-a-Box to aid in streamlining the adoption of GenAI by enterprises. It also launched Nutanix Data Services for Kubernetes, to provide consistent data services across virtual machines and container assets, and Nutanix Kubernetes Platform to allow simplification in the management of modern applications on-premise and in native public cloud service.</div>
<div>Nutanix announced a collaboration with NVIDIA to aid enterprises adopt GenAI easily.</div>
<div>Nutanix Cloud Clusters enable workloads to run seamlessly in private and public clouds while increasing automation and reducing the dependency on expensive proprietary solutions.</div>
<h2>Elongated Sales Cycle Concern for Nutanix</h2>
<div>In fiscal 2024, Nutanix&#39;s land and expand revenues suffered due to longer sales cycles, which have been elongated compared to historical levels.</div>
<div>NTNX&#39;s average contract term length in the fiscal fourth quarter was 3.1 years, 0.1 years higher than the fiscal third quarter.</div>
<div>Nutanix&#39;s customer base is increasing but is largely constituted of large deals leading to variability of timing and outcome.</div>
<div>As NTNX targets its sales efforts for large enterprises, it faces higher costs, greater competition, stiff price pressure, customization challenges, and lower predictability in its ability to complete the sale.</div>
<div>NTNX&#39;s operating expense for fiscal 2024 was $1.51 billion, up 7% over fiscal 2023. This increase can be attributed to an increase in research and development (increased 19% to $638 million) and sales and marketing expenses (increased 6% to $977 million). Higher operating expenses are likely to negatively impact bottom-line results in fiscal 2025.</div>
<h2>NTNX&#39;s Fiscal 2025 Outlook Positive</h2>
<div>For fiscal 2025, NTNX revenues are estimated in the range of $2.435-$2.465 billion, indicating year-over-year growth of 14% at the mid-point.</div>
<div>The Zacks Consensus Estimate for revenues is pegged at $2.45 billion, indicating year-over-year growth of 14.24%.</div>
<div>NTNX expects a non-GAAP operating margin in the band of 15.5-17%.</div>
<div>The consensus mark for fiscal 2025 earnings is pegged at $1.40 per share, up 2.9% in the past 30 days. The figure indicates a 6.87% year-over-year increase.</div>
<div>Nutanix expects free cash flow in the range of $540-$600 million, suggesting a free cash flow margin of 23% at the midpoint.</div>
<h2>NTNX Shares - To Buy, Hold or Sell?</h2>
<div>Macroeconomic challenges, including persistent inflation, are a concern for NTNX&#39;s prospects.</div>
<div>Stretched valuation, elongated sales cycle duration, and increasing operating expenses are concerns for investors.</div>
<div>Nutanix currently has a Zacks Rank #3 (Hold), which implies that investors should wait for a more favorable entry point into the stock.</div>
<div><a href="https://www.zacks.com/stock/news/2347040/nutanix-shares-up-26-ytd-how-should-investors-play-the-stock?cid=CS-BENZ-FT-analyst_blog|rank_focused-2347040">To read this article on Zacks.com click here.</a></div>
</div>


Earnings

Large Cap

Macro Economic Events

Penny Stocks

Contracts

Small Cap

Economics

Markets

Tech

Trading Ideas

CRNC

EVLV

NTNX

Nutanix Shares Up 26% YTD: How Should Investors Play the Stock?

<p>Wells Fargo  analyst Joseph O'Dea   maintains Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with a Overweight and raises the price target from $640 to $710.</p>


Wells Fargo Maintains Overweight on Parker Hannifin, Raises Price Target to $710

<ul>
<li>Credelio Quattro&#x2122; (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms, roundworms, hookwormsii and three different species of tapeworm that other brands skip creating a gap in coverageiii</li>
<li>Warming temperatures and changing consumer habits have increased parasite pressure and spread across geographies, bringing with them increased public health risk.</li>
<li>Experts recommend monthly treatment for zoonotic parasitesiv, like <i>Echinococcus granulosus</i>, a type of tapeworm.</li>
<li>Credelio Quattro launch expected in first quarter of 2025</li>
</ul>
<p>GREENFIELD, Ind., Oct. 7, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) today announced the U.S. Food and Drug Administration (FDA) has approved Credelio Quattro&#x2122; (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), becoming the broadest approved canine oral parasiticide with its protection against six types of parasites—fleas, ticks, heartworms, and the three risky intestinal parasites—roundworms, hookwormsii and tapeworms. Credelio Quattro is a single, monthly chewable tablet for dogs eight weeks of age or older.</p>


Biotech

General

Elanco Receives FDA Approval For Credelio Quattro, The Broadest Canine Oral Parasiticide Protection In A Single Monthly Dose; Launch Expected In Q1 2025

<p>Wells Fargo  analyst Joseph O'Dea   maintains Otis Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) with a Equal-Weight and raises the price target from $95 to $108.</p>


OTIS

Wells Fargo Maintains Equal-Weight on Otis Worldwide, Raises Price Target to $108

<p>Wells Fargo  analyst Joseph O'Dea   maintains Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) with a Equal-Weight and raises the price target from $570 to $615.</p>


Wells Fargo Maintains Equal-Weight on Lennox Intl, Raises Price Target to $615

<p><strong>Sonder Holdings Inc. (NASDAQ:</strong><a href="https://www.benzinga.com/stock/SOND#NASDAQ"><strong>SOND</strong></a><strong>, "Sonder" or the "Company"))) </strong>today announced that it has received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that since it remains delinquent in filing its Forms 10-Q for the periods ended March 31 and June 30, 2024 (the "Forms 10-Q"), respectively (the "Delinquent Filings"), the Staff has determined that the Company is non-compliant with Nasdaq Listing Rule 5250(c)(1). Previously, the Staff granted the Company an exception until September 30, 2024, to file all delinquent periodic reports. Additionally, the Company was previously deemed delayed on the filing of the&nbsp;Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"); however, the Company has since filed the 2023 Form 10-K on September 27, 2024, and the Staff determined that the Company complies with respect to the 2023 Form 10-K. As a result of the Delinquent Filings, the Company's common stock and warrants are subject to suspension in trading on October 10, 2024, and delisting from Nasdaq unless the Company appeals and requests a hearing before a Hearings Panel ("Hearings Panel") by 4:00 Eastern Time on October 8, 2024.</p>


SOND

Sonder Holdings Receives Nasdaq Staff Determination Letter; Has Requested Hearing Before Hearings Panel

<p>Insulation Supplies was established in 1986 and is headquartered in New Hope, Minnesota, near Minneapolis. Insulation Supplies generates over&nbsp;$22 million&nbsp;of annual revenue throughout Minnesota and the upper Midwest.</p>
<p>As a specialty distributor focused on residential and commercial end-markets, Insulation Supplies sells fiberglass insulation, spray foam insulation, cellulose insulation, and related insulation accessories and machinery.</p>


Installed Building Products Reveals Acquisition Of Wholesale Insulation Supply, Inc. Doing Business As Insulation Supplies; No Terms Disclosed; Deal Adds Over $22M Of Annual Revenue

<p>Wells Fargo  analyst Joe O'Dea   maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Overweight and raises the price target from $80 to $84.</p>


Wells Fargo Maintains Overweight on Johnson Controls Intl, Raises Price Target to $84

<p>Wells Fargo  analyst Joseph O'Dea   maintains Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) with a Overweight and raises the price target from $100 to $110.</p>


Wells Fargo Maintains Overweight on Ingersoll Rand, Raises Price Target to $110

<p><i><strong>CHS and Denim Health are working together to enhance patient experience and generate efficiencies across CHS' proprietary call center that serves approximately 1,000 primary care providers</strong></i></p>
<p>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) ("CHS") and Denim Health have announced a development partnership that is aimed at revolutionizing the call center experience for patients through the implementation of conversational AI in the CHS Patient Access Center ("PAC"). The PAC is a centralized call center serving nearly 1,000 CHS-affiliated primary care providers and handling more than 25,000 inbound calls daily.</p>
<p>CHS and Denim Health have been working together since late 2023 to develop call center workflows that incorporate conversational AI. Following a successful pilot, CHS has deployed Denim Health's AI bot across the PAC environment, making this advanced technology available for all inbound calls.</p>
<p>In the initial phase, conversational AI is being used to authenticate the identity of callers, understand the reason for their calls, and capture additional information to assist agents, before transferring callers to PAC agents. Denim Health's AI bot has successfully authenticated the identities of existing patients with zero instances of misidentification. In cases where the bot is unable to verify a caller's identity, the call is seamlessly transferred to a PAC agent for further assistance.</p>
<p>This use case already has resulted in a notable reduction in total call time, creating immediate efficiencies. The enterprise-wide deployment also lays the groundwork for additional use cases, which will include using conversational AI, machine learning, and natural language processing to enable patient self-scheduling, care gap closures, and other common transactions.</p>
<p>While consumers have become increasingly comfortable completing call center interactions using bots and automated systems, callers to the CHS Patient Access Center retain the option to speak with a human agent at any time during their call experience.</p>


Community Health Systems And Denim Health Announce A Development Partnership Designed To Broadly Scale Conversational AI Across The CHS Patient Access Center That Serves ~1,000 Primary Care Providers

TD Cowen analyst Marc Frahm maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today. The company's shares opened today at $8...

TD Cowen Sticks to Its Buy Rating for Scholar Rock Holding (SRRK)

ClearBridge Small Cap Value Strategy Q2 2024 Commentary

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) and keeping the price tar...

Buy Rating Justified by Scholar Rock's Promising Drug Trials and Market Potential

Invesco Health Care Fund Q2 2024 Review

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Curis (CRIS – Research Report), Scholar Rock Holding...

Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Scholar Rock Holding (SRRK) and Travere Therapeutics (TVTX)

Wedbush analyst David Nierengarten maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today and set a price target of $27.00....

Wedbush Sticks to Its Buy Rating for Scholar Rock Holding (SRRK)

Scholar Rock Holding ( ($SRRK) ) has provided an announcement. Scholar Rock Holding Corporation has announced promising results from its Phase 3 SA...

Scholar Rock's SMA Treatment Trials Show Promising Results

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) today and set a price target o...

Buy Rating on Scholar Rock Holding: Promising Phase 3 Results and Strategic FDA/EMA Submissions Drive Positive Outlook

Scholar Rock surges 335% on phase 3 spinal muscular atrophy candidate data

Scholar Rock announces proposed public offering of common stock, pre-funded warrants

ACHC

ADMA

ALGT

ALNY

AZNCF

BKDT

BRKR

CFCV

CNVVF

CNVVY

CORT

CRIS

CRTO

DXCM

FWRD

HLMN

INFR

INTU

IONS

KYTX

LEGN

LNTH

LRGE

MRUS

MUSA

NATL

NCRRP

NONOF

NVDA

PGNY

PODD

PRIM

QDEL

REGN

RGEN

SGRY

SKYW

SRRK

TCBX

TECH

TMCI

TSLA

TVTX

VBTX

VEEV

VRTX

YLDE

Press Releases

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Abivax

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Annexon

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Celcuity

Emergent BioSolutions

Exscientia Plc - American Depositary Shares

Exscientia

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Humacyte

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Neurogene

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

PureTech Health plc - American Depositary Shares

PureTech Health

Q32 Bio

Regenxbio

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Reneo Pharmaceuticals

Stoke Therapeutics

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Y-mAbs Therapeutics

Wedbush

JP Morgan

BMO Capital

HC Wainwright & Co.

Truist Securities

Scholar Rock Holding shares are trading higher after the company announced topline results from the Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab in patients with SMA. The study achieved its primary endpoint.

Comments

Scholar Rock Holding

Notizie

Ultime notizie per Scholar Rock Holding (NASDAQ:SRRK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO